News/ News/ R&D NewAmsterdam goes public to advance drug in abandoned class Phil Taylor cardiovascular, cholesterol, Merck & Co, NewAmsterdam Pharma, obicetrapib, R&D 0 Comment NewAmsterdam Pharma has charted out a route to a Nasdaq listing by merging with black cheque company Frazier Share X NewAmsterdam goes public to advance drug in abandoned class https://pharmaphorum.com/news/newamsterdam-goes-public-to-advance-drug-in-abandoned-class/